172 related articles for article (PubMed ID: 37704946)
21. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
[TBL] [Abstract][Full Text] [Related]
22. Development of an Immune Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Tumor Microenvironment.
Wang M; Song Q; Song Z; Xie Y
Horm Metab Res; 2023 Jun; 55(6):402-412. PubMed ID: 37192644
[TBL] [Abstract][Full Text] [Related]
23. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
24. Accurate prognostic prediction for patients with clear cell renal cell carcinoma using a ferroptosis-related long non-coding RNA risk model.
Xiang X; Guo Y; Chen Z; Zhang F; Qin Y
Cancer Biomark; 2023; 37(2):95-107. PubMed ID: 37248883
[TBL] [Abstract][Full Text] [Related]
25. NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.
Zheng B; Wang S; Yuan X; Zhang J; Shen Z; Ge C
BMC Urol; 2023 May; 23(1):82. PubMed ID: 37138262
[TBL] [Abstract][Full Text] [Related]
26. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
[TBL] [Abstract][Full Text] [Related]
27. Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma.
Liu Y; Shi Z; Zheng J; Zheng Z; Sun H; Xuan Z; Bai Y; Fu M; Du Y; Shao C
Front Immunol; 2023; 14():1171883. PubMed ID: 37056778
[TBL] [Abstract][Full Text] [Related]
28. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
29. PIWI-Interacting RNA Pathway Genes: Potential Biomarkers for Clear Cell Renal Cell Carcinoma.
Heng B; Xie X; Zeng W; Li H; Shi L; Ye W; Wu F
Dis Markers; 2022; 2022():3480377. PubMed ID: 35273654
[TBL] [Abstract][Full Text] [Related]
30. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
31. Identification of candidate biomarker
Lv Q; Xiao W; Xiong Z; Shi J; Miao D; Meng X; Yuan H; Yang H; Zhang X
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1176-1190. PubMed ID: 34856762
[No Abstract] [Full Text] [Related]
32. Expression of gasdermin D in clear cell renal cell carcinoma and its effect on its biological function.
Zhang J; Wang Y; Ma J; Aimudula A
Front Oncol; 2023; 13():1163714. PubMed ID: 37483501
[TBL] [Abstract][Full Text] [Related]
33. The novel role of LDHA/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma.
Chen J; Wu F; Cao Y; Xing Y; Liu Q; Zhao Z
PeerJ; 2023; 11():e15749. PubMed ID: 37547725
[TBL] [Abstract][Full Text] [Related]
34. The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases.
Liu T; Nie J; Zhang X; Deng X; Fu B
Sci Rep; 2023 May; 13(1):7442. PubMed ID: 37156847
[TBL] [Abstract][Full Text] [Related]
35. Identification of an independent immune-genes prognostic index for renal cell carcinoma.
Li G; Wei X; Su S; Wang S; Wang W; Wang Y; Meng X; Xia J; Song N; Qin C
BMC Cancer; 2021 Jun; 21(1):746. PubMed ID: 34187413
[TBL] [Abstract][Full Text] [Related]
36. A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma.
Chen S; Zhang E; Guo T; Shao J; Wang T; Zhang N; Wang X; Zheng J
BMC Cancer; 2022 Jan; 22(1):1. PubMed ID: 34979993
[TBL] [Abstract][Full Text] [Related]
37. Construction of an immune-related prognostic model by exploring the tumor microenvironment of clear cell renal cell carcinoma.
He J; Zhong Y; Sun Y; Xie C; Yu T
Anal Biochem; 2022 Apr; 643():114567. PubMed ID: 35122734
[TBL] [Abstract][Full Text] [Related]
38. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
Gao J; Ye F; Han F; Jiang H; Zhang J
Front Immunol; 2022; 13():956679. PubMed ID: 36177018
[TBL] [Abstract][Full Text] [Related]
39. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
[TBL] [Abstract][Full Text] [Related]
40. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
